Karo Pharma AB | Ownership
Companies that own Karo Pharma AB
Nordea Investment Management AB
3,634,492
2.21%
3,358,037
0.05%
12/29/2017
Dimensional Fund Advisors LP
1,019,792
0.62%
173,154
0%
04/30/2018
Swedbank Robur Fonder AB
587,135
0.36%
0
0%
07/31/2018
BlackRock Investment Management (UK) Ltd.
458,430
0.28%
458,430
0%
07/31/2018
SEB Investment Management AB
390,044
0.24%
155,417
0%
12/31/2017
SSgA Funds Management, Inc.
313,457
0.19%
878
0%
09/06/2018
Lyxor International Asset Management SAS
296,049
0.18%
0
0%
09/05/2018
E. Öhman J :or Fonder AB
169,785
0.1%
169,785
0.01%
12/31/2017
BlackRock Advisors (UK) Ltd.
132,444
0.08%
0
0%
09/06/2018
Skandia Investment Management AB
57,356
0.04%
0
0%
07/31/2018
| Address |
Nybrokajen 7
Stockholm AB 111 48
Sweden
|
|
Employees
|
- |
| Website |
http://www.karopharma.se |
| Updated |
07/08/2019 |
| Karo Pharma AB is a healthcare company, which engages in the research, development, and distribution of innovative drugs for key medical needs. It focuses on the project portfolio consists of RORgamma, Multiple Sclerosis and Cancer, and T268A Common Cold Spray. The company was founded in 1987 and is headquartered in Stockholm, Sweden. |
